GT-20029
Pharmaceutical compound
From Wikipedia, the free encyclopedia
GT-20029, also known as AR-PROTAC, is an androgen receptor degradation enhancer which is under development for the treatment of androgenetic alopecia (male-pattern hair loss) and acne.[1][3][4] It is used topically in gel form.[1][2]
| Clinical data | |
|---|---|
| Other names | GT20029; AR-PROTAC |
| Routes of administration | Topical[1][2] |
| Drug class | Androgen receptor degradation enhancer |
The drug acts as an androgen receptor (AR) proteolysis targeting chimera (PROTAC), facilitating the degradation of the AR via enhancement of ubiquitin-mediated proteolysis.[4][5][2][6] It has been found to block the AR-mediated miniaturization of hair follicles in preclinical research.[6]
GT-20029 is under development by Suzhou Kintor Pharmaceuticals.[1][3] As of September 2024, it is in phase 2 clinical trials and is advancing to phase 3 trials.[1][3][7] The chemical structure of GT-20029 does not yet appear to have been disclosed.[4]
See also
- List of investigational acne drugs
- List of investigational hair loss drugs
- Pyrilutamide (KX-826)
- Clascoterone (Winlevi; Breezula; CB-03-01)